Our findings show that FTH1 is a vital player in ferroptosis resistance in HNSCCs and that a combination of ferroptosis-inducers and EGFR inhibitions could be a promising target strategy for HNSCC therapy. Here, EGFR is linked to head and neck squamous cell carcinoma.